<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018979</url>
  </required_header>
  <id_info>
    <org_study_id>TG-0054-02</org_study_id>
    <nct_id>NCT01018979</nct_id>
  </id_info>
  <brief_title>Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients</brief_title>
  <official_title>A Phase II, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiGen Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TaiGen Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell
      mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD).</measure>
    <time_frame>1 week</time_frame>
    <description>Patients who met the target CD34+ cell collection of ≧2 x 106 cells/kg after two apheresis sessions were classified as achieving mobilization success.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</measure>
    <time_frame>36 hrs after infusion</time_frame>
    <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Increase of Circulating CD34+ Cell Counts in Peripheral Blood.</measure>
    <time_frame>Baseline, 3 hours and 6 hours after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at Which Maximum Plasma Concentration is Observed (Tmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</measure>
    <time_frame>36 hrs after infusion</time_frame>
    <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t1/2) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</measure>
    <time_frame>36 hrs after infusion</time_frame>
    <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Rate Constant (λz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</measure>
    <time_frame>36 hrs after infusion</time_frame>
    <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Time t of TG-0054 in 12 Consented Patients With MM, NHL or HD.</measure>
    <time_frame>36 hrs after infusion</time_frame>
    <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Infinity of TG-0054 in 12 Consented Patients With MM, NHL or HD.</measure>
    <time_frame>36 hrs after infusion</time_frame>
    <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</measure>
    <time_frame>36 hrs after infusion</time_frame>
    <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at the Terminal State (Vz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</measure>
    <time_frame>36 hrs after infusion</time_frame>
    <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</measure>
    <time_frame>36 hrs after infusion</time_frame>
    <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating CD34+ Cell Counts in Peripheral Blood.</measure>
    <time_frame>Baseline, 3 hours and 6 hours after infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>TG-0054 (2.24 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TG-0054 (3.14 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG-0054 (2.24 mg/kg)</intervention_name>
    <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
    <arm_group_label>TG-0054 (2.24 mg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG-0054 (3.14 mg/kg)</intervention_name>
    <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
    <arm_group_label>TG-0054 (3.14 mg/kg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 to 70 years of age inclusive

          -  Patients with confirmed pathology diagnosis of MM, NHL or HD

          -  Potential candidate for autologous stem cell transplantation at Investigator's
             discretion

          -  ≦ 2 prior regimens of cytotoxic chemotherapy (rituximab, thalidomide, and bortezomib
             will not be considered as cytotoxic chemotherapy)

          -  &gt; 4 weeks since last cycle of chemotherapy prior to the study drug administration

          -  Total dose of melphalan received ≦ 200 mg in the most recent chemotherapy treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Recovered from all acute toxic effects of prior chemotherapy at Investigator's
             discretion

          -  White blood cell (WBC) count ≧ 3.0 x 109/L on screening laboratory assessments

          -  Absolute neutrophil count ≧ 1.5 x 109/L on screening laboratory assessments

          -  Platelet count ≧ 100 x 109/L on screening laboratory assessments

          -  Serum creatinine ≦ 2.2 mg/dL on screening laboratory assessments

          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin
             &lt; 2 x upper limit of normal (ULN) on screening laboratory assessments

          -  Negative for human immunodeficiency virus (HIV)

          -  Adequate cardiac and pulmonary function to undergo leukapheresis at Investigator's
             discretion

          -  For females, one of the following criteria must be fulfilled:

               1. At least one year post-menopausal, or

               2. Surgically sterile, or

               3. Willing to use a double-barrier method [intrauterine device (IUD) plus condom,
                  spermicidal gel plus condom] of contraception throughout the study

          -  Males must be willing to use a reliable form of contraception (use of a condom or a
             partner fulfilling the above criteria) from study Day 1 until 28 days after the last
             dose of TG-0054

          -  Able to provide the signed informed consent

        Exclusion Criteria:

          -  Received radiation therapy around the pelvic or spinal area within 6 months prior to
             the study drug administration

          -  &gt;10% bone marrow involvement of lymphoma in NHL patients

          -  Failed previous stem cell collection [failed to collect 2 x 106 CD34+ cells/kg within
             4 apheresis sessions after receiving granulocyte colony-stimulating factor (G-CSF)]

          -  Patients who have undergone previous stem cell transplantation procedure

          -  Received G-CSF within 2 weeks prior to the study drug administration

          -  History of other cancer within the past 5 years excluding MM, NHL, HD, basal cell or
             squamous cell carcinoma of the skin

          -  History of other hematologic disorders including bleeding or thromboembolic disease

          -  History of poor and uncontrollable cardiovascular or pulmonary disease such as
             myocardial infarction, cardiac arrhythmias, transient ischemic attack, stroke or
             Chronic Obstructive Pulmonary Disease (COPD) patients hospitalized more than two times
             a year due to underlying disease

          -  Diagnosis of sickle cell anemia or documented sickle cell trait

          -  Uncontrollable malignancy with MM, NHL or HD, or carcinomatous meningitis, at
             Investigator's discretion

          -  Any infection required antibiotic treatment or unexplained fever above 38 °C within 3
             days prior to dosing

          -  Pregnant or breast-feeding

          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
             treatment of either a psychiatric or physical (e.g., infectious disease) illness must
             not be enrolled into this study

          -  Received any other investigational drug within 1 month before entering the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tzeon-Jye Chiou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tso-Fu Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddist Tzu Chi General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheng-Fung Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chih-Cheng Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang-Gung Memorial Hospital Chiayi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Po-Nan Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jih-Luh Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital Chiayi</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital Linkou</name>
      <address>
        <city>Linkou</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <results_first_submitted>December 18, 2014</results_first_submitted>
  <results_first_submitted_qc>January 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 15, 2015</results_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 20 subjects were randomized. Among these, 19 subjects met all eligibility criteria and received at least one dose of TG-0054.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TG-0054 (2.24 mg/kg)</title>
          <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
        </group>
        <group group_id="P2">
          <title>TG-0054 (3.14 mg/kg)</title>
          <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13">A total of 20 subjects were randomized.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Peak CD34+ cell count in PB &lt; 10 cell/uL</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not received at least one dose</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>19 subjects met all eligibility criteria and received at least one dose of TG-0054.</population>
      <group_list>
        <group group_id="B1">
          <title>TG-0054 (2.24 mg/kg)</title>
          <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
        </group>
        <group group_id="B2">
          <title>TG-0054 (3.14 mg/kg)</title>
          <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.3" spread="15.5"/>
                    <measurement group_id="B2" value="52.4" spread="9.3"/>
                    <measurement group_id="B3" value="50.5" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.7" spread="10.1"/>
                    <measurement group_id="B2" value="158.7" spread="8.6"/>
                    <measurement group_id="B3" value="160.2" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="23.1"/>
                    <measurement group_id="B2" value="60.6" spread="10.2"/>
                    <measurement group_id="B3" value="63.1" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilogram/ meter^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="6.0"/>
                    <measurement group_id="B2" value="24.0" spread="3.0"/>
                    <measurement group_id="B3" value="24.4" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Multiple myeloma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hodgkin lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hodgkin disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD).</title>
        <description>Patients who met the target CD34+ cell collection of ≧2 x 106 cells/kg after two apheresis sessions were classified as achieving mobilization success.</description>
        <time_frame>1 week</time_frame>
        <population>In TG-0054 (2.24 mg/kg) group, A total of 4 patients (2 with MM, 1 with NHL, and 1 with HD) underwent apheresis procedure.
In TG-0054 (3.14 mg/kg) group, A total of 3 patients (1 with MM and 2 with NHL) underwent apheresis procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>TG-0054 (2.24 mg/kg)</title>
            <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
          <group group_id="O2">
            <title>TG-0054 (3.14 mg/kg)</title>
            <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD).</title>
          <description>Patients who met the target CD34+ cell collection of ≧2 x 106 cells/kg after two apheresis sessions were classified as achieving mobilization success.</description>
          <population>In TG-0054 (2.24 mg/kg) group, A total of 4 patients (2 with MM, 1 with NHL, and 1 with HD) underwent apheresis procedure.
In TG-0054 (3.14 mg/kg) group, A total of 3 patients (1 with MM and 2 with NHL) underwent apheresis procedure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NHL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
        <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
        <time_frame>36 hrs after infusion</time_frame>
        <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>TG-0054 (2.24 mg/kg)</title>
            <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
          <group group_id="O2">
            <title>TG-0054 (3.14 mg/kg)</title>
            <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
          <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
          <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20971" spread="6995"/>
                    <measurement group_id="O2" value="29665" spread="18583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Increase of Circulating CD34+ Cell Counts in Peripheral Blood.</title>
        <time_frame>Baseline, 3 hours and 6 hours after infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multiple Myeloma (MM)</title>
            <description>7 patients with MM were enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Non-Hodgkin Lymphoma (NHL) + Hodgkin Disease (HD)</title>
            <description>10 patients and 2 patients with NHL and HD were enrolled, respectively.</description>
          </group>
          <group group_id="O3">
            <title>All Patients</title>
            <description>All patents = MM + NHL + HD</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Increase of Circulating CD34+ Cell Counts in Peripheral Blood.</title>
          <units>fold</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fold increase (3 hours after infusion)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="5.9"/>
                    <measurement group_id="O2" value="6.1" spread="6.1"/>
                    <measurement group_id="O3" value="6.4" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fold increase (6 hours after infusion)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="7.2"/>
                    <measurement group_id="O2" value="7.8" spread="10.4"/>
                    <measurement group_id="O3" value="7.8" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fold increase (Maximum increase)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="7.5"/>
                    <measurement group_id="O2" value="10.3" spread="8.9"/>
                    <measurement group_id="O3" value="10.0" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analyze whether the mean fold increase from the baseline to the peak time change was significant or not.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>P values less than 0.05 are considered statistically significant in this study.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyze whether the mean fold increase from the baseline to the peak time change was significant or not.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <p_value_desc>P values less than 0.05 are considered statistically significant in this study.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time at Which Maximum Plasma Concentration is Observed (Tmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
        <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
        <time_frame>36 hrs after infusion</time_frame>
        <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>TG-0054 (2.24 mg/kg)</title>
            <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
          <group group_id="O2">
            <title>TG-0054 (3.14 mg/kg)</title>
            <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
        </group_list>
        <measure>
          <title>Time at Which Maximum Plasma Concentration is Observed (Tmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
          <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
          <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0"/>
                    <measurement group_id="O2" value="0.25" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (t1/2) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
        <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
        <time_frame>36 hrs after infusion</time_frame>
        <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>TG-0054 (2.24 mg/kg)</title>
            <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
          <group group_id="O2">
            <title>TG-0054 (3.14 mg/kg)</title>
            <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (t1/2) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
          <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
          <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" spread="0.4"/>
                    <measurement group_id="O2" value="4.28" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Rate Constant (λz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
        <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
        <time_frame>36 hrs after infusion</time_frame>
        <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>TG-0054 (2.24 mg/kg)</title>
            <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
          <group group_id="O2">
            <title>TG-0054 (3.14 mg/kg)</title>
            <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant (λz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
          <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
          <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.01"/>
                    <measurement group_id="O2" value="0.16" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Time t of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
        <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
        <time_frame>36 hrs after infusion</time_frame>
        <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>TG-0054 (2.24 mg/kg)</title>
            <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
          <group group_id="O2">
            <title>TG-0054 (3.14 mg/kg)</title>
            <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Time t of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
          <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
          <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43610" spread="7034"/>
                    <measurement group_id="O2" value="55814" spread="12153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Infinity of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
        <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
        <time_frame>36 hrs after infusion</time_frame>
        <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>TG-0054 (2.24 mg/kg)</title>
            <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
          <group group_id="O2">
            <title>TG-0054 (3.14 mg/kg)</title>
            <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Infinity of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
          <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
          <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43713" spread="7039"/>
                    <measurement group_id="O2" value="55920" spread="12170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
        <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
        <time_frame>36 hrs after infusion</time_frame>
        <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>TG-0054 (2.24 mg/kg)</title>
            <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
          <group group_id="O2">
            <title>TG-0054 (3.14 mg/kg)</title>
            <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
          <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
          <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
          <units>mL/ hr/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" spread="9.4"/>
                    <measurement group_id="O2" value="58.6" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at the Terminal State (Vz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
        <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
        <time_frame>36 hrs after infusion</time_frame>
        <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>TG-0054 (2.24 mg/kg)</title>
            <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
          <group group_id="O2">
            <title>TG-0054 (3.14 mg/kg)</title>
            <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at the Terminal State (Vz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
          <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
          <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351" spread="62"/>
                    <measurement group_id="O2" value="366" spread="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State (Vss) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
        <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
        <time_frame>36 hrs after infusion</time_frame>
        <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>TG-0054 (2.24 mg/kg)</title>
            <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
          <group group_id="O2">
            <title>TG-0054 (3.14 mg/kg)</title>
            <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss) of TG-0054 in 12 Consented Patients With MM, NHL or HD.</title>
          <description>Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.</description>
          <population>According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.</population>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" spread="64"/>
                    <measurement group_id="O2" value="193" spread="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulating CD34+ Cell Counts in Peripheral Blood.</title>
        <time_frame>Baseline, 3 hours and 6 hours after infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multiple Myeloma (MM)</title>
            <description>7 patients with MM were enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Non-Hodgkin Lymphoma (NHL) + Hodgkin Disease (HD)</title>
            <description>10 patients and 2 patients with NHL and HD were enrolled, respectively.</description>
          </group>
          <group group_id="O3">
            <title>All Patients</title>
            <description>All patents = MM + NHL + HD</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating CD34+ Cell Counts in Peripheral Blood.</title>
          <units>cells/μL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PB CD34+ count (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.7"/>
                    <measurement group_id="O2" value="0.9" spread="0.5"/>
                    <measurement group_id="O3" value="1.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PB CD34+ count (3 hours after infusion)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="4.0"/>
                    <measurement group_id="O2" value="4.0" spread="2.1"/>
                    <measurement group_id="O3" value="4.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PB CD34+ count (6 hours after infusion)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="3.9"/>
                    <measurement group_id="O2" value="4.3" spread="2.7"/>
                    <measurement group_id="O3" value="5.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PB CD34+ count (Maximum increase)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="4.4"/>
                    <measurement group_id="O2" value="5.2" spread="3.7"/>
                    <measurement group_id="O3" value="6.5" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The whole study period, from Visit 1 (screening, day -14) to Visit 9 (7 days after the last dose)</time_frame>
      <desc>There were 8 serious AEs (SAE) reported that were all unrelated to study drug. No AEs led to discontinuation of study drug treatment and there were no deaths reported in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>TG-0054 (2.24 mg/kg)</title>
          <description>TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
        </group>
        <group group_id="E2">
          <title>TG-0054 (3.14 mg/kg)</title>
          <description>TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ADMISSION FOR PREPARATION OF PERIPHERAL BLOOD STEM CELL HARVEST</sub_title>
                <description>Post-treatment SAE. Definitely not related to study drug</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>AUTOLOGOUS STEM CELL TRANSPLANT</sub_title>
                <description>Post-treatment SAE. Definitely not related to study drug</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HOSPITALIZATION FOR BONE MARROW TRANSPLANTATION</sub_title>
                <description>Post-treatment SAE. Definitely not related to study drug</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION</sub_title>
                <description>Post-treatment SAE. Definitely not related to study drug</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>TREATMENT OF NON-HODGKIN LYMPHOMA</sub_title>
                <description>Post-treatment SAE. Definitely not related to study drug</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PEIPHERAL BLOOD STEM CELL HARVEST</sub_title>
                <description>Post-treatment SAE. Definitely not related to study drug</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <description>Post-treatment Ae. 3 possible related and 2 probably related.</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <description>Post-treatment AE. Probably related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <description>Post-treatment AE. 1 probably related and 1 definitely related.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>EMESIS</sub_title>
                <description>Post-treatment AE. Definitely not related to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>MILD ABDOMINAL PAIN</sub_title>
                <description>Post-treatment AE. Probably related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>MILD DIARRHEA</sub_title>
                <description>Post-treatment AE. Probably related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <description>Post-treatment AE. Probably related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ECCHYMOSIS OVER FEMORAL PUNCTURE SITE</sub_title>
                <description>Post-treatment AE. Definitely not related to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>FEVER</sub_title>
                <description>Post-treatment AE. Possible related to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ABNORMAL DATA OF INCREASE BILIRUBIN</sub_title>
                <description>Post-treatment AE. Probably not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>CARDIAC DISORDERS-OTHER:QT PROLONG AT 24HR-36HR AFTER INFUSION</sub_title>
                <description>Post-treatment AE. Possible related to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>INCREASE ALANINE AMINOTRANS-FERASE</sub_title>
                <description>Post-treatment AE. Probably not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>INCREASE ALPHA-GANNA GLUTAMYL TRANSPEPTIDASE</sub_title>
                <description>Post-treatment AE. Probably not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERCALCEMIA</sub_title>
                <description>Post-treatment AE. All possible related to study drug.</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPOCALCEMIA</sub_title>
                <description>Post-treatment AE. Definitely not related to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPOCALCIUM</sub_title>
                <description>Post-treatment AE. Definitely not related to study drug.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPOKALEMIA</sub_title>
                <description>Post-treatment AE. Probably not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>LOW BACK PAIN</sub_title>
                <description>Post-treatment AE. Probably related to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CLONIC OF RIGHT KNEE</sub_title>
                <description>Post-treatment AE. Definitely not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <description>Post-treatment AE. 2 definitely not related and 1 possible related.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>MILD DIZZINESS</sub_title>
                <description>Post-treatment AE. Possible related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>MILD HEADACHE</sub_title>
                <description>Post-treatment AE. Possible related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>NUMBNESS OF FACE</sub_title>
                <description>Post-treatment AE. Definitely not related to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>NUMBNESS OF FACE AND PALM</sub_title>
                <description>Post-treatment AE. Definitely not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>NUMBNESS OF FACE HANDS AND LEGS</sub_title>
                <description>Post-treatment AE. Definitely not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>NUMBNESS OF LEGS AND LIPS</sub_title>
                <description>Post-treatment AE. Definitely not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>NUMBNESS OF LIPS</sub_title>
                <description>Post-treatment AE. Definitely not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST TIGHTNESS</sub_title>
                <description>Post-treatment AE. Probably not related to study drug.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>DRY COUGH</sub_title>
                <description>Post-treatment AE. Definitely not related.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ITCHY SKIN</sub_title>
                <description>Post-treatment AE. Probably not related to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <description>Post-treatment AE. Definitely not related to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <description>Post-treatment AE. Definitely not related to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPOTENSION BP 82/51MMHG</sub_title>
                <description>Post-treatment AE. Possible related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPOVOLEMIC HYPOTENSION BP 78/56MMHG</sub_title>
                <description>Post-treatment AE. Possible related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI needs to inform sponsor and asks for permission before he/she discusses or publishes trial results after the trial is completed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chen-En Tsai, M.D., Ph.D.</name_or_title>
      <organization>TaiGen Biotechnology Co., Ltd.</organization>
      <phone>+886-2-8177-7072 ext 1211</phone>
      <email>cetsai@taigenbiotech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

